Core Insights - AbbVie has effectively managed the loss of exclusivity for Humira by launching two new immunology drugs, Skyrizi and Rinvoq, with significant sales expected in the upcoming quarterly report [1][3][8] Group 1: Drug Performance and Sales Expectations - Skyrizi and Rinvoq have been launched across major indications previously covered by Humira, including a new indication for atopic dermatitis, showing strong performance particularly in inflammatory bowel disease (IBD) [2] - AbbVie anticipates combined sales of $6 billion for Skyrizi and Rinvoq in the second quarter, with individual estimates of $4 billion for Skyrizi and $2 billion for Rinvoq [3][8] Group 2: Expansion in Other Therapeutic Areas - AbbVie is also expanding its oncology and neuroscience portfolios, adding new therapies such as Epkinly, Elahere, and Emrelis, bringing its total oncology therapies to five [4] - The neuroscience segment has seen growth driven by increased uptake of migraine treatments, Ubrelvy and Qulipta [4] Group 3: Competitive Landscape - The immunology market is highly competitive, with key players like Johnson & Johnson and Eli Lilly also expanding their portfolios. Johnson & Johnson is focusing on Tremfya after Stelara lost patent exclusivity [5] - Eli Lilly has recently received FDA approval for Omvoh, marking its entry into the IBD market, which enhances its immunology offerings [6] Group 4: Valuation and Market Performance - AbbVie shares have outperformed the industry year to date, trading at a price/earnings (P/E) ratio of 14.21, slightly below the industry average of 15.01 [7][10] - The bottom-line estimate for AbbVie in 2025 remains at $12.28, with a slight increase in the 2026 estimate from $14.05 to $14.06 [11]

Key Takeaways PFE expects steady 2025 COVID sales but anticipates major LOE losses and IRA headwinds in the future. Medicare Part D changes may cut into sales of key PFE drugs like Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE trades at 7.82x forward earnings, below industry average, with EPS estimates rising for 2025 and 2026.Pfizer (PFE) is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and ...

Key Takeaways LLY's Mounjaro and Zepbound now generate 50% of revenues and drive strong growth despite recent headwinds. ABBV expects $24.7B in 2025 sales from Skyrizi and Rinvoq, helping offset Humira's post-LOE revenue decline. LLY expects 32% sales growth in 2025, but ABBV boasts rising estimates and a lower valuation.Eli Lilly (LLY) and AbbVie (ABBV) are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, strong market capitalization and global footprint. Both com ...

Key Takeaways PFE stock is down 10.7% YTD, underperforming its industry, sector, and the broader market. COVID product sales are falling, but oncology drugs and Seagen assets are boosting top-line growth. PFE trades well below peers in terms of valuation and offers a 7.4% dividend yield with rising EPS estimates.Pfizer’s (PFE) stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below ...

Core Viewpoint - Pfizer's stock has seen a 5% increase following its first-quarter earnings report, which showed earnings growth but a decline in sales, primarily due to lower revenues from key products and the impact of Medicare Part D redesign [1][2][24]. Financial Performance - Pfizer reported earnings of 92 cents per share, a 12% increase year-over-year, while revenues declined by 6% on an operational basis [1]. - The company maintains its revenue outlook for 2025, projecting total revenues between $61.0 billion and $64.0 billion, with earnings expected in the range of $2.80 to $3.00 per share [2]. - The stock has declined 7.3% year-to-date, underperforming the industry, which has increased by 2.4% [15][17]. Product Sales and Market Trends - Sales of COVID-related products, Comirnaty and Paxlovid, are projected to drop to around $11 billion in 2024 from $56.7 billion in 2022, with similar expectations for 2025 [5]. - Non-COVID operational revenues improved in 2024, driven by key products like Vyndaqel, Padcev, and newly acquired products from Seagen [6][7]. Oncology Segment - Pfizer has a strong position in oncology, with a 7% growth in oncology revenues in the first quarter of 2025, supported by drugs like Xtandi and Padcev [8][9]. - The acquisition of Seagen has further strengthened Pfizer's oncology portfolio, with several candidates entering late-stage development [8][9]. Challenges and Headwinds - Pfizer anticipates a moderate negative impact on revenues from the loss of exclusivity for several key products in 2025, with significant effects expected from 2026 to 2030 [11]. - The company expects an unfavorable impact of approximately $1 billion from the Medicare Part D redesign under the Inflation Reduction Act, particularly affecting higher-priced drugs [12]. - Pfizer has faced setbacks, including the discontinuation of the GLP-1R agonist danuglipron due to safety concerns [13]. Strategic Outlook - Pfizer is focused on cost reductions and internal restructuring, aiming for savings of $7.7 billion by the end of 2027, which should support profit growth [25]. - The company returned $2.4 billion to shareholders through dividends in the first quarter of 2025, with a dividend yield of around 7.1% [26]. - Despite challenges, Pfizer's diversified portfolio and new growth prospects position it well for long-term gains, making it attractive for value and income investors [24][28].